208 related articles for article (PubMed ID: 17675651)
1. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
Waites CR; Dominick MA; Sanderson TP; Schilling BE
Toxicol Sci; 2007 Nov; 100(1):248-58. PubMed ID: 17675651
[TBL] [Abstract][Full Text] [Related]
2. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
Tannehill-Gregg SH; Sanderson TP; Minnema D; Voelker R; Ulland B; Cohen SM; Arnold LL; Schilling BE; Waites CR; Dominick MA
Toxicol Sci; 2007 Jul; 98(1):258-70. PubMed ID: 17426106
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
4. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
5. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
Dominick MA; White MR; Sanderson TP; Van Vleet T; Cohen SM; Arnold LE; Cano M; Tannehill-Gregg S; Moehlenkamp JD; Waites CR; Schilling BE
Toxicol Pathol; 2006; 34(7):903-20. PubMed ID: 17178691
[TBL] [Abstract][Full Text] [Related]
6. Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.
Yao M; Swaminathan A; Srinivas N
Biopharm Drug Dispos; 2007 Jan; 28(1):35-42. PubMed ID: 17117455
[TBL] [Abstract][Full Text] [Related]
7. Subchronic urinary bladder effects of muraglitazar in male rats.
Van Vleet TR; White MR; Sanderson TP; Cohen SM; Cano M; Arnold LL; Waites CR; Schilling BE; Mitroka J; Dominick MA
Toxicol Sci; 2007 Mar; 96(1):58-71. PubMed ID: 17132713
[TBL] [Abstract][Full Text] [Related]
8. Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.
Guo Y; Jolly RA; Halstead BW; Baker TK; Stutz JP; Huffman M; Calley JN; West A; Gao H; Searfoss GH; Li S; Irizarry AR; Qian HR; Stevens JL; Ryan TP
Toxicol Sci; 2007 Apr; 96(2):294-309. PubMed ID: 17255113
[TBL] [Abstract][Full Text] [Related]
9. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.
Zhang D; Raghavan N; Wang L; Xue Y; Obermeier M; Chen S; Tao S; Zhang H; Cheng PT; Li W; Ramanathan R; Yang Z; Humphreys WG
Drug Metab Dispos; 2011 Jan; 39(1):123-31. PubMed ID: 20876787
[TBL] [Abstract][Full Text] [Related]
10. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
12. The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Pruimboom-Brees IM; Francone O; Pettersen JC; Kerlin RL; Will Y; Amacher DE; Boucher GG; Morton D
Toxicol Pathol; 2012 Jul; 40(5):810-8. PubMed ID: 22504321
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.
Suzuki S; Arnold LL; Pennington KL; Kakiuchi-Kiyota S; Wei M; Wanibuchi H; Cohen SM
Toxicol Sci; 2010 Feb; 113(2):349-57. PubMed ID: 19858066
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Devasthale PV; Chen S; Jeon Y; Qu F; Shao C; Wang W; Zhang H; Cap M; Farrelly D; Golla R; Grover G; Harrity T; Ma Z; Moore L; Ren J; Seethala R; Cheng L; Sleph P; Sun W; Tieman A; Wetterau JR; Doweyko A; Chandrasena G; Chang SY; Humphreys WG; Sasseville VG; Biller SA; Ryono DE; Selan F; Hariharan N; Cheng PT
J Med Chem; 2005 Mar; 48(6):2248-50. PubMed ID: 15771468
[TBL] [Abstract][Full Text] [Related]
15. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Geese WJ; Achanzar W; Rubin C; Hariharan N; Cheng P; Tomlinson L; Ordway N; Dracopoli NC; Delmonte T; Hui L; Krishnan B; Cosma G; Ranade K
Pharmacogenet Genomics; 2008 Oct; 18(10):903-10. PubMed ID: 18794727
[TBL] [Abstract][Full Text] [Related]
16. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
17. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
18. Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Rogue A; Renaud MP; Claude N; Guillouzo A; Spire C
Toxicol Appl Pharmacol; 2011 Jul; 254(1):18-31. PubMed ID: 21515302
[TBL] [Abstract][Full Text] [Related]
19. Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
Bopst M; Atzpodien EA
Regul Toxicol Pharmacol; 2017 Jun; 86():107-116. PubMed ID: 28274810
[TBL] [Abstract][Full Text] [Related]
20. Urine acidification has no effect on peroxisome proliferator-activated receptor (PPAR) signaling or epidermal growth factor (EGF) expression in rat urinary bladder urothelium.
Achanzar WE; Moyer CF; Marthaler LT; Gullo R; Chen SJ; French MH; Watson LM; Rhodes JW; Kozlosky JC; White MR; Foster WR; Burgun JJ; Car BD; Cosma GN; Dominick MA
Toxicol Appl Pharmacol; 2007 Sep; 223(3):246-56. PubMed ID: 17663016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
